A way out or a new prospect: The future development of autologons hematopoietic stem cell transplantation in type 1 diabetes therapy
10.3760/cma.j.issn.1000-6699.2012.06.001
- VernacularTitle:自体造血干细胞移植治疗1型糖尿病的前景与出路
- Author:
Weiqiong GU
;
Guang NING
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 1;
Hematopoietic stem cells;
Transplantation;
Immune
- From:
Chinese Journal of Endocrinology and Metabolism
2012;28(6):445-447
- CountryChina
- Language:Chinese
-
Abstract:
The direetion of radical treatment ( complete remission ) for type 1A diabetes is to correct immune disorder and to full repair damaged pancreatic islet cells.It includes the application of immune modulators and islet β-cell replacement therapy.Autologous hematopoietic stem cell transplantation (AHSCT) is a new promising approach for the treatment of type 1A diabetes by reconstitution of immunotolerance and promoting β-cell regeneration.The candidates for AHSCT are limited to the people with early-onset diabetes and keeping obvious residual islet β-cell function.Because of the potential mechanisms underlying the action of AHSCT is still not very clear,careful balancing of the pros and coins of A HSCT is still needed by further trials and intensive studies.
